<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283737</url>
  </required_header>
  <id_info>
    <org_study_id>STU-BIO-T-XX-001-01</org_study_id>
    <nct_id>NCT01283737</nct_id>
  </id_info>
  <brief_title>Use of Demineralised Bone Matrix (DBX) in Osteochondritis Dissecans (OCD)</brief_title>
  <official_title>A Randomized, Subject-blind, Controlled Pilot Trial to Evaluate the Effectiveness and Safety of the Use of Demineralized Bone Matrix (DBX®) Versus Mosaicplasty in the Treatment of Late-Stage Osteochondritis Dissecans (OCD) of the Knee in Patients With a Mature Skeleton</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synthes GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synthes GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 1:1 randomised pilot study in 30 patients in 1 site in Helsinki, Finland.&#xD;
&#xD;
      The investigators hypothesize that function, pain, type and quality of cartilage in adult&#xD;
      patients with osteochondritis dissecans of the knee will be better in the DBX group compared&#xD;
      to the mosaicplasty group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Brittberg-Peterson functional assessment score from baseline until 12 months post-op</measure>
    <time_frame>At enrollment (day -7), at full weight-bearing (6-8 weeks post-operative), 6 months post-operative, 12 months post-operative</time_frame>
    <description>Score 0-130 (see Clin Orthop Relat Res 2000 May;374:212-34) to assess function and pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type and quality of the formed cartilage to assess the effectiveness of the treatment</measure>
    <time_frame>12 months post-operative</time_frame>
    <description>The type and quality of the newly formed cartilage will be assessed with arthroscopy and/or MRI /dGEMRIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with complications to assess the safety of the use of the treatment</measure>
    <time_frame>Enrolment (day -7) until 12 months post-operative</time_frame>
    <description>All adverse events and complications will be recorded throughout the trial and assessed for severity and causality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteochondritis Dissecans</condition>
  <arm_group>
    <arm_group_label>DBX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DBX Putty in glass syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mosaicplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBX Putty</intervention_name>
    <description>OCD of the knee will be treated with DBX Putty</description>
    <arm_group_label>DBX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mosaicplasty</intervention_name>
    <description>Mosaicplasty procedure performed to treat OCD of the knee</description>
    <arm_group_label>Mosaicplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, age between 18 years and 65 years&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             at the time of inclusion&#xD;
&#xD;
          -  Females of childbearing potential must be willing to use effective means of birth&#xD;
             control for at least 1 year post surgery. Medically acceptable contraceptives include:&#xD;
&#xD;
               1. Surgical sterilisation&#xD;
&#xD;
               2. Approved hormonal contraceptives&#xD;
&#xD;
               3. Barriers methods combined with a spermicide&#xD;
&#xD;
               4. An intrauterine device&#xD;
&#xD;
               5. Abstinence alone is not considered an acceptable method of contraception&#xD;
&#xD;
          -  Late stage Osteochondritis Dissecans (ICD-10 code M93.2) of the knee classified as&#xD;
             stage III or IV (Anderson MRI classification)&#xD;
&#xD;
          -  Mature skeleton&#xD;
&#xD;
          -  Written informed consent prior to any study specific procedures (except the procedures&#xD;
             necessary to determine eligibility)&#xD;
&#xD;
          -  Ability and willingness to comply with all study specific procedures, including&#xD;
             attending all follow-up visits up to 12 months postoperative and completing&#xD;
             questionnaires in a local language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 1 knee affected&#xD;
&#xD;
          -  Patients who can be treated with conservative treatment alone, unless there is&#xD;
             evidence of at least 6 months failed previous treatment&#xD;
&#xD;
          -  Systemic disease including AIDS, HIV, Hepatitis or any other disease that would&#xD;
             prevent normal organ and marrow function.&#xD;
&#xD;
          -  Patients undergoing systemic cortisone treatment or immunosuppressive therapy (e.g.&#xD;
             avascular necrosis)&#xD;
&#xD;
          -  Patients undergoing active cancer therapy (chemotherapy, radiation treatment).&#xD;
&#xD;
          -  History of alcohol abuse or illegal drug use.&#xD;
&#xD;
          -  Participation in any other device or drug trial within 3 months prior to the inclusion&#xD;
             in the study&#xD;
&#xD;
          -  Presence of at least one contraindication for DBX® Putty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jari Salo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Töölö Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Töölö Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteochondritis Dissecans</keyword>
  <keyword>OCD</keyword>
  <keyword>Mosaicplasty</keyword>
  <keyword>Demineralised Bone Matrix</keyword>
  <keyword>DBX</keyword>
  <keyword>DBX Putty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteochondritis</mesh_term>
    <mesh_term>Osteochondritis Dissecans</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

